DocSartor

Meet Oliver Sartor, M.D.

Dr. Oliver Sartor is the C.E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology at Tulane University School of Medicine. He also serves as assistant dean for oncology. He is a world-renowned prostate cancer expert and one of the few medical oncologists in the world to focus on prostate cancer. Combining basic, translational and clinical prostate cancer research and ensuring state-of- the-art clinical treatment have been the major areas of focus throughout his career.

Funds raised through the One Man Shoot will be used to support Dr. Sartor’s ongoing research initiatives and Tulane’s Prostate Cancer Research Program.

tulane1

Tulane’s Prostate Cancer Program Is Unparalleled

Dr. Sartor is the leader of Tulane’s Prostate Cancer Research Program, a world-class team of cancer professionals performing cutting-edge basic and clinical research and running the largest treatment center for prostate cancer patients in Louisiana. Thousands of prostate cancer patients are treated in Tulane’s clinics each year. In addition to patients from Louisiana, Tulane has cancer patient referrals from 26 additional states and seven countries outside the United States.

Tulane is also at the cutting-edge of groundbreaking basic and clinical research into prostate cancer. Between 2010- 2013, the U.S. Food and Drug Administration approved six new drugs for the treatment of advanced prostate cancer. Dr. Oliver Sartor played a lead role in the development of two of these drugs and served in an advisory role for two others. This is unprecedented progress, as these are the first new treatment options offering hope for men with advanced disease since 2004, and Tulane’s prostate program contributed to their development. Our goals, of course, are to be even better tomorrow and to continue to build our program. With your help, we are able to do just that.

The Complete Spectrum Of Prostate Cancer Research And Care

Tulane Cancer Center provides cancer prevention, diagnosis, treatment, and rehabilitation with an emphasis on convenience for our patients and their families and with a team approach to comprehensive prostate cancer care. Our world-class program spans the full spectrum of prostate cancer care - from basic and clinical research to cancer screening and prevention to early detection and diagnosis to the latest treatment options and rehabilitation. Working alongside Dr. Sartor, Tulane’s Prostate Cancer Team includes other world-class clinicians, plus laboratory scientists who study cancer at the molecular level. The ultimate goal is to explore new avenues in the hopes of better understanding cancer and how to cure it.

Research Grant Funding & Publication In Prestigious Medical Journals

The answer to curing prostate cancer is research and clinical trials. Tulane Cancer Center’s prostate cancer faculty have successfully competed for millions in federal and other research funding in recent months. This is particularly impressive, considering lower federal research budgets and greatly increased competition for these dollars across the United States. Additionally, Dr. Sartor and his colleagues have had the results of their research published in a number of prestigious, high-impact medical journals. Publication often involves a rigorous peer-review process and once again indicates the importance of their work. Since January 1, 2017, Dr. Sartor has had approximately 40 manuscripts published in journals such as Lancet Oncology, The New England Journal of Medicine, Journal of the American Medical Association and Nature Reviews Urology. For a complete list of Dr. Sartor’s publications, please visit www.pubmed.gov and enter Sartor O (or Sartor AO) in the search bar.

Clinical Trials Lead To New Treatment Options

Tulane offers a variety of clinical research trials for the treatment of prostate cancer. Two international trials in which Dr. Sartor played key roles revealed significant results in 2017.

The first showed that African-American men treated with the immunotherapy drug sipuleucel-T had a median nine-month overall survival advantage compared to Caucasian men with the disease, according to an analysis of 1,900 patients who received the treatment between 2011 and 2013. Dr. Sartor, lead author of the study, presented these data at the 112th American Urological Association annual meeting in Boston last year. “This is the first time that I have ever seen a prostate cancer treatment seemingly work better in African Americans,” said Sartor. “These new findings are very encouraging given that African-American men with prostate cancer have a mortality rate more than twice as high as Caucasian men and historically have presented with aggressive disease and have had worse outcomes in both real-world settings and controlled clinical trials.”

The second study, which was the lead article in the Feb. 2, 2017, issue of The New England Journal of Medicine, showed that adding two years of hormonal therapy to radiation treatment significantly improves survival rates for patients whose cancer returned years after surgery to remove the organ. “It more than cut the risk of prostate cancer death in half, which is quite substantial,” said Dr. Sartor. “For the first time, we now have a demonstration that hormonal therapy added to radiation can help save lives for men who have recurrent prostate cancer after surgery. That’s a very big statement.” Dr. Oliver Sartor was co-author of the study and medical oncology chair of the national committee that ran the nearly two decades-long trial. He said the study will likely help shift the standard of care for the approximately 30 percent of prostate cancer patients whose cancer returns.

Early Detection & Complimentary Cancer Screenings

When cancer is found early, it is more successfully treated. The Tulane Cancer Center offers complimentary prostate cancer screenings on the second Tuesday of each month. Participants are asked to complete a brief questionnaire regarding family history and provide a blood sample. To make an appointment for a complimentary screening, please call 504-988-5800 or 1-800-588-5800.

Emotional & Family Support

The Patricia Trost Friedler Center for Psychosocial Oncology at Tulane Cancer Center offers psychological, emotional, and educational support for our prostate cancer patients and their family members through a number of services, including individual and family counseling, a variety of support groups, wellness workshops, and a resource library.

Tulane’s Department of Urology also hosts bi-monthly Prostate Cancer Support Group meetings featuring guest speakers who address topics of interest to prostate cancer patients and their families. Support groups provide an opportunity for patients to share knowledge and experiences. For more information, please contact the Department of Urology at 504-988-2750.

“I would like to extend my deepest thanks to everyone involved in the One Man Shoot Sporting Clays Fundraiser – the planning committee members, shooters, sponsors, in-kind donors, and volunteers. I am deeply appreciative of the faith you have placed in our program, and I am committed to leveraging your support to advance our shared goal of eradicating prostate cancer—for those who have valiantly fought the battle, for those fighting still, and for those who may be diagnosed in the future. By working to- gether to make progress through innovative basic and clinical research efforts, through productive national and international collaborations, and through aggressive pursuit and application of breakthroughs in information and technology, we can aspire to a future where our sons and grandsons will worry much less about a prostate cancer diagnosis. I am humbled and honored to share this journey with you and to have your support along the way. Thank you for making it possible to continue this fight!” - Oliver Sartor, M.D.